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Abstract Tryptophan hydroxylase (TPH) catalyses L-tryptophan into 5-hydroxy-L-tryptophan, which is the first and rate-
limiting step of serotonin (5-HT) biosynthesis. Earlier, we found that TPH2 up-regulated in the hippocampus of postnatal
rats after the oral treatment of Bacopa monniera leaf extract containing the active compound bacosides. However, the
knowledge about the interactions between bacosides with TPH is limited. In this study, we take advantage of in silico
approach to understand the interaction of bacoside-TPH complex using three different docking algorithms such as Hex-
Dock, PatchDock and AutoDock. All these three algorithms showed that bacoside A and A3 well fit into the cavity consists
of active sites. Further, our analysis revealed that major active compounds bacoside A3 and A interact with different
residues of TPH through hydrogen bond. Interestingly, Tyr235, Thr265 and Glu317 are the key residues among them, but
none of them are either at tryptophan or BH4 binding region. However, its note worthy to mention that Tyr 235 is a
catalytic sensitive residue, Thr265 is present in the flexible loop region and Glu317 is known to interacts with Fe.
Interactions with these residues may critically regulate TPH function and thus serotonin synthesis. Our study suggested that
the interaction of bacosides (A3/A) with TPH might up-regulate its activity to elevate the biosynthesis of 5-HT, thereby
enhances learning and memory formation.
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1 Introduction
Bacopa monniera L. (Scrophulariaceae), commonly known
as Brahmi, is a creeping plant with bitter taste found in
marshy areas in India. It is used in the Indian system of
ayurvedic medicine to enhance cognitive function. The leaf
extract of B. monniera contains bioactive compounds
bacosides A1–A3 [1–3], bacopasaponins A–G [4–7] and
bacopasides I–V [8, 9]. A study claimed that bioactive
compounds extracted from B. monniera improved acqui-
sition, consolidation and retention of newly acquired
behavior in rats [10]. Subsequent studies demonstrate that
these compounds significantly attenuated the phenytoin
[11], diazepam [12], hypobaric hypoxia [13], L-NNA [14],
scopolamine [15], mCPBG [16] and D-galactose [17]
induced memory impairments in rats. B. monniera treat-
ment modulates various neurotransmitters such as acetyl-
choline (ACh), serotonin (5-hydroxytryptamine, 5-HT),
gamma amino butyric acid (GABA), glutamate (Glu) and
dopamine (DA) at different brain regions to enhance the
cognitive functions [16, 18–24].
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It has been documented that variations in serotonin
metabolism and transmission is often associated with
changes in short and long-term memory [25–28]. Biosyn-
thesis of serotonin is regulated by the rate-limiting enzyme
tryptophan hydroxylase (TPH) (EC. 1. 14. 16. 4), which
converts L-tryptophan to 5-hydroxy-L-tryptophan using
molecular oxygen, non-heme iron (II) with tetrahydrobi-
opterin (BH4) as a cofactor [29, 30]. There are two forms of
TPH; TPH1 is responsible for most peripheral 5-HT,
whereas, TPH2 is neuronal specific [31–34]. Isoforms of
TPH (TPH1, TPH2) are highly homologous with an iden-
tity of 68–71 % across the phyla, and possess similar three-
dimensional structure with respect to the location of amino
acid residues where the substrate binds or the active site
geometry [35]. TPH2 holds different kinetic properties like
higher specificity for L-tryptophan but a lower catalytic
efficiency. It has higher molecular weight than TPH1
because of the elongated N-terminal domain (approx.
56 kDa compared to TPH1 which is 51 kDa) and also
possess an additional phosphorylation site [36]. Studies
indicate that up-regulation of TPH expression leads to an
enhancement of TPH activity and 5-HT synthesis [37, 38].
Recently, we found that the administration of B. mon-
niera leaf extract in postnatal rats elevates the 5-HT level
by up-regulating tryptophan hydroxylase-2 (TPH2) and
serotonin transporter (SERT) expression [24]. Thus the
elevated 5-HT level influences learning and memory by
modulating other ACh and Glu, acting through the 5-HT3
receptor [16]. The structure of TPH with Fe and its cofactor
BH2 complex have been documented [39]. However, the
interaction between bacoside A and TPH was not studied
yet. Based on the limitations, as a first attempt we adopted
in silico approach to study the complex interactions. At this
point, we used three different automatic molecular docking
algorithms such as AutoDock, PatchDock and HexDock to
identify interactions between the complexes. Through
various interactions, molecular recognition occurs between
protein and ligand, which is critical for identifying binding
partners to the binding site. Our in silico study showed the
interaction of bacosides (A3, A) with TPH, which is
believed to be involved in the up-regulation of 5-HT
synthesis.
2 Results and Discussion
To uncover the structural basis of docking interactions
between TPH and bacosides, we sought to determine the
complex formation. Number of active compounds was
identified for therapeutic targets based on the binding of
ligand with protein, in which virtual screening and com-
putational tools plays a major role [40, 41]. Bacosides are
non-polar glycosides; lipid-mediated transportation by
passive diffusion may facilitate transport across blood–brain
barrier [8, 9, 42] and interact with TPH2. The general 3D
molecular structure with combination of bacoside-TPH
showed that the bioactive compounds present in the B.
monniera leaf extract interact with TPH, which may up-
regulate TPH2 expression [24]. In our study, we tested
bacoside-TPH interactions in three different algorithms
developed based on combinations of various scoring func-
tions. This would help us to identify the true hits and reduce
the errors [43]. After finding its interactions with bacoside A
and A3, we have found out that both plugs into a hydrophobic
pocket of TPH. Further, our analysis showed that all the three
docking algorithms identified similar residues (Tyr235,
Thr265, Pro268, His272, Glu317, Phe318, Ser337, Glu340,
Ile 366) surrounding (within 3.0 A˚) bacoside A as best hit
and interacts with different residues of TPH. However,
HexDock and PatchDock (Fig. 1b) identified that Thr265
(1.46 and 1.91 A˚) is the residue involved in hydrogen bond,
where as AutoDock identified Glu 317 (1.79 A˚) as an
interacting residue (Fig. 1). Bacoside A – TPH complex
showed docking score of 5002 with atomic contact energy
-291.73. In addition, the estimated free energy for the
complex is -9.29 kcal/mol with an inhibition constant (Ki)
of 156.17 nM. Similarly, all the three docking algorithms
showed Tyr235, Thr265, Pro268, Glu317, Ser337 and
Cys364 residues (within 3.0 A˚) in the pocket of the TPH
surrounding bacoside A3. Among them all the three docking
algorithm identified different residues Thr265 (1.91 A˚)
(Fig. 2a), Tyr235 (2.96 A˚) (Fig. 2b) and Glu317 (2.48 A˚)
(Fig. 2c) interacting with bacoside A3 through hydrogen
bond. Bacoside A3 with TPH complex showed docking score
of 5472 with atomic contact energy -424.37. Further, we
noted -10.23 kcal/mol as a estimated free energy for
bacoside A3-TPH complex with the Ki of 37.36 nM.
In the present study, our in silico analysis showed that
bacosides (A3, A) interact with TPH. We found that the
bacoside A3 showed higher interaction score when com-
pared to the interaction of bacoside A with TPH. The
bioactive compounds: bacoside A and A3 formed hydrogen
bond with TPH at two key residues Glu317 and Tyr235. Its
note worthy to mention that tryptophan binds with Leu124-
Asp139 and Ile367-Thr369 loop regions of TPH which are
involved in conformational change [44, 45]. Interestingly,
except Glu317 (O of Glu317 with H- of bacosides), the
bacosides binding amino acids were not present at either
the tryptophan or the co-factor BH4 (Gly 234, Leu 236, His
251, Glu 273, Glu 317) binding sites [44, 45]. In fact, we
found that bacoside A3 and A formed hydrogen bond with
Glu317. Although Glu317 of TPH bound with Fe, it also
interacts with bacoside A3/A at a different side chain.
Notably, bacoside A, A3 interact with Thr265, which is in
the line of active site channel of TPH (residue 263–269 and
363–372) having high B-factor and less electron density
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[39]. It appears that these regions are highly flexible and
the interaction at this site might enhance the TPH activity,
possibly the reason for the observed elevated level of TPH
activity [24]. Further, our analysis showed that bacoside A3
interacts with Tyr235 of TPH, which is conserved in all
known TPH. Specific mutants of Tyr235 increase the Km
for substrate (L-Trp) and lower Km for cofactor (BH4) [46].
These interactions add additional insight into the function
of bacoside in 5-HT synthesis.
3 Conclusion
Our in silico analysis showed that the bacosides (A3, A)-
TPH complex interact through hydrogen bond with specific
sites. These specific sites are known to regulate the cata-
lytic mechanism of TPH [44–46], bacosides interactions
may facilitate TPH activity and thus enhance the synthesis
of serotonin [24]. Further study in bacosides interaction
with different mutated TPH may provide greater insight in
understanding the effect of bacosides in serotonergic sys-
tem for the potential applications.
4 General Experimental Procedures
The PDB format of TPH enzyme (PDB ID: 1MLW) was
retrieved from protein data bank. Likewise, the chemical
structures of bioactive compounds Bacoside A (Compound
ID: 53398644), Bacoside A3 (Compound ID: 44152167)
were collected from database (http://pubchem.ncbi.nlm.nih.
gov) and then converted as protein data using OpenBabel
[47] and docked with TPH. Different algorithms such as
AutoDock [48], PatchDock [49] and HexDock [50] was used
based on complementary shape principles matching two
molecules by searching complementary to each other. Any
type molecules (proteins, DNA, peptides, drugs) can be
docked in PatchDock. A wide interface is ensured to include
several matched local features of the docked molecules that
have complementary characteristics. The molecules
Fig. 1 3D molecular structure from combination of TPH and bacoside A generated using HexDock (a), PatchDock (b) and AutoDock
(c) showing the interactions with key residues
Fig. 2 TPH and bacoside A complex 3D molecular structure generated using HexDoc (a), PatchDock (b) and AutoDock (c) showing the
interactions with key residues Thr265, Tyr235 and Glu317 respectively
Molecular Docking of Bacosides with Tryptophan Hydroxylase 253
123
detected as concave are matched with convex and flat pat-
ches. Then the candidate transformation generated by pat-
ched with complementary patches. Each candidate
transformation is further evaluated by a scoring function that
considers both geometric fit and atomic desolvation energy.
Finally, an RMSD (root mean square deviation) clustering is
applied to the candidate solutions to discard redundant
solutions [40]. The remaining matched candidates are ranked
according to the geometric shape complementarity score.
The generated TPH and bacoside three-dimension (3D)
molecule complex was further analyzed by the Swiss-pdb
viewer (ver 4.1). An algorithm has been used to identify the
hydrophobic and hydrogen bond interaction, based on the
distance between ligand–protein atoms, which is below
3.0 A˚ [51].
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